|
1000
|
Abstract/Summary
|
-
<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Background</jats:title>
<jats:p>The standard treatment for patients with advanced HER2-positive gastric cancer is a combination of the antibody trastuzumab and platin-fluoropyrimidine chemotherapy. As some patients do not respond to trastuzumab therapy or develop resistance during treatment, the search for alternative treatment options and biomarkers to predict therapy response is the focus of research. We compared the efficacy of trastuzumab and other HER-targeting drugs such as cetuximab and afatinib. We also hypothesized that treatment-dependent regulation of a gene indicates its importance in response and that it can therefore be used as a biomarker for patient stratification.</jats:p>
</jats:sec><jats:sec>
<jats:title>Methods</jats:title>
<jats:p>A selection of gastric cancer cell lines (Hs746T, MKN1, MKN7 and NCI-N87) was treated with EGF, cetuximab, trastuzumab or afatinib for a period of 4 or 24 h. The effects of treatment on gene expression were measured by RNA sequencing and the resulting biomarker candidates were tested in an available cohort of gastric cancer patients from the VARIANZ trial or functionally analyzed in vitro.</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>After treatment of the cell lines with afatinib, the highest number of regulated genes was observed, followed by cetuximab and trastuzumab. Although trastuzumab showed only relatively small effects on gene expression, <jats:italic>BMF</jats:italic>, <jats:italic>HAS2</jats:italic> and <jats:italic>SHB</jats:italic> could be identified as candidate biomarkers for response to trastuzumab. Subsequent studies confirmed <jats:italic>HAS2</jats:italic> and <jats:italic>SHB</jats:italic> as potential predictive markers for response to trastuzumab therapy in clinical samples from the VARIANZ trial. <jats:italic>AREG</jats:italic>, <jats:italic>EREG</jats:italic> and <jats:italic>HBEGF</jats:italic> were identified as candidate biomarkers for treatment with afatinib and cetuximab. Functional analysis confirmed that <jats:italic>HBEGF</jats:italic> is a resistance factor for cetuximab.</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>By confirming <jats:italic>HAS2</jats:italic>, <jats:italic>SHB</jats:italic> and <jats:italic>HBEGF</jats:italic> as biomarkers for anti-HER therapies, we provide evidence that the regulation of gene expression after treatment can be used for biomarker discovery.</jats:p>
<jats:p>Trial registration.</jats:p>
<jats:p>Clinical specimens of the VARIANZ study (NCT02305043) were used to test biomarker candidates.</jats:p>
</jats:sec>
|
|
1000
|
Hinweis
|
-
DeepGreen-ID: db2e4e2ea6f2433bb1d2d351f4b72b57 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
|
